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HER2/neu overexpression is a driving force in the carcinogenesis of several human cancers. In breast cancer the prognostic influence
of HER2/neu was shown to be at least partly based on increased metastatic potential mediated by the chemokine–chemokine
receptor pair SDF-1(CXCL12)/CXCR4. We wanted to evaluate the influence of HER2/neu on ovarian cancer prognosis and to
investigate whether compromised survival would correlate with CXCR4 expression and/or SDF-1 abundance. Therefore, we analysed
HER2/neu, CXCR4, and SDF-1 in 148 ovarian tumour samples by means of immunohistochemistry on tissue microarrays.
Overexpression of HER2/neu was found in 27.6% of ovarian cancer tissues and in 15% of ovarian borderline tumours. In ovarian
cancer patients, overexpression of HER2/neu correlated closely with overall survival (univariate hazard ratio (HR) 2.59, P¼0.005;
multiple corrected HR 1.92, P¼0.074). In contrast, CXCR4 expression and SDF-1 abundance had no impact on overall survival, and
both parameters were not correlated with HER2/neu expression. As expected, cytoplasmic CXCR4 expression and SDF-1 abundance
correlated closely (Po0.0001). Our results confirm a univariate influence of HER2/neu expression on overall survival, which was
completely independent of the expression of CXCR4 and the abundance of SDF-1, implying significant differences between the HER2/
neu downstream pathways in ovarian cancer compared with breast cancer.
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Epithelial ovarian cancer is the most lethal gynaecologic malig-
nancy and with about 6% the fourth most frequent cause of
cancer-related death of women in Western countries. Estimates
indicate that one in 70 women will develop ovarian cancer in her
lifetime, with a median survival rate of 4.5 years. A recent cancer
statistic reported an estimated 22200 new cases and 16210 deaths
per year in the United States (Jemal et al, 2005). Early diagnosis is
a major challenge, as more than three-quarter of cases are
diagnosed in late stages. Ovarian cancer metastasises preferentially
to the local lymph nodes and the peritoneum, and in contrast to
breast cancer, only rarely in other organs like liver, lung, and
bones.
The majority of hereditary ovarian cancer cases are caused by
germline mutations in BRCA1 and BRCA2, the so-called breast/
ovarian cancer syndrome. Mutations in these caretaker genes set
the scene for further genomic and epigenomic aberrations, which
ultimately transform healthy cells into cells with perturbed cell
cycle control and metastatic potential. The starting point of
sporadic cases may differ but the sequence of events is not well
described to date, for ovarian cancer in particular.
Ovarian cancer and breast cancer share the overexpression of
HER2/neu, a member of the HER family of receptor tyrosine
kinases triggering signalling pathways which control cell growth,
differentiation, motility, and adhesion. In breast cancer, the
prognostic value of HER2/neu expression is well established and
the therapeutic modulation of this oncogene by antibodies or small
molecules is a classic example of targeted therapy. The situation in
ovarian cancer is less clear (recently reviewed in Serrano-Olvera
et al, 2006), with contradicting results of HER2/neu expression in
the prognosis of the disease and very little available data on its
potential for therapeutic manipulations, prompting us to investi-
gate HER2/neu expression and its potential consequences in
ovarian cancer.
For breast cancer, it was shown that HER2/neu mediated tumour
metastasis, and survival prognosis is essentially driven by
upregulation of the chemokine receptor CXCR4, a membrane-
bound G-protein-coupled receptor (Li et al, 2004). The chemokine
was first described in its function as a key regulator of the homing
process of lymphocytes to inflammatory tissues (Bleul et al, 1997).
In previous reports dealing with CXCR4 expression in neoplastic
diseases nuclear, cytoplasmic, and membrane staining was found
by means of immunohistochemistry. Recently, for breast cancer, it
was shown that only cytoplasmic staining of CXCR4 had significant
impact on prognosis, but not nuclear staining – using the same
antibody as we used for our study (Salvucci et al, 2005). Three
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sprevious studies identified nuclear localisation of CXCR4 in
hepatocellular carcinoma (Shibuta et al, 2002), invasive ductal
mammary carcinoma (Kato et al, 2003), and non-small-cell lung
cancer (NSCLC) (Spano et al, 2004). Strong CXCR4 nuclear
staining was associated with significantly better outcome in early-
stage NSCLC (Spano et al, 2004). The natural ligand of CXCR4, the
stromal cell-derived factor (SDF-1 or CXCL12), is highly expressed
in lung, liver, and lymph nodes (Phillips et al, 2003), the preferred
organs for metastasis of several tumours.
To contribute to the controversial discussion about the influence
of HER2/neu overexpression on ovarian cancer prognosis and
whether the chemokine receptor system SDF-1/CXCR4 is signifi-
cantly involved in this process, we examined the expression of
these three potential oncoproteins by means of immunohisto-
chemistry on tissue microarrays comprising 148 ovarian cancer
patients.
MATERIALS AND METHODS
Ovarian tissue microarray and immunohistochemistry
For immunohistochemical studies, paraffin material available from
primary diagnosis was used. Patients gave informed consent
according to the criteria of the Medical University of Vienna.
Relevant clinical information was collected and tissue samples and
clinical data anonymised. A tissue microarray was composed by
taking core needle ‘biopsies’ from specific locations in the
preexisting paraffin-embedded tissue blocks and re-embedding
them in an arrayed master block, using techniques and an
apparatus developed by Beecher Instruments Inc., Micro-Array
Technology (Sun Prairie, WI, USA). To achieve good representa-
tion of the tumour, three biopsies of tumour material were selected
from each patient. Using this technology, each tissue sample was
treated in an identical manner and the entire cohort was analysed
in one batch on three slides. Reagent conditions, incubation times
and temperatures, wash conditions, and antigen retrieval (if
necessary) were held identical for each case. A 4–5mm paraffin
section of the tissue microarray was deparaffinised (xylene) and
rehydrated (incubation in serial dilutions of ethanol), and,
subsequently, the sections were treated with 0.2% H2O2/PBS (pH
7.4) to quench endogenous peroxidases. After blocking with 2%
normal serum (from the animal in which the secondary antibody
was raised) for 30min, the sections were incubated at 41C
overnight with primary antibodies (CXCR4, mouse monoclonal
anti-human CXCR4 (MAB172) (R&D Systems, Minneapolis, MN,
USA); SDF-1, mouse monoclonal anti-human/mouse SDF-1/
CXCL12 antibody (MAB350) (R&D Systems); HER2/neu (DAKO,
Glostrup, Denmark); and HercepTest (DAKO, Glostrup,
Denmark). As secondary antibody for CXCR4 and SDF-1,a n
anti-mouse Ig, horseradish peroxidase-linked whole antibody from
sheep (NA 931, Amersham, Buckinghamshire, UK) was utilised.
Staining was performed using a staining kit from DAKO: DAKO
Cytomation Liquid DABþsubstrate (Glostrup, Denmark). DAKO
HercepTest was carried out and stained as described by the
manufacturer. Positive and negative control slides (as appropriate)
were stained within the same batch with the tissue microarrays and
examined before evaluation of the tissue microarrays.
Data analyses and statistics
Staining of the tissue microarrays was interpreted by two
independent pathologists. Classification of all three tissue micro-
arrays was performed at once to ensure reliability and reprodu-
cibility. Staining for CXCR4 was classified in ‘1’ (missing or very
low cytoplasmic expression), ‘2’ (medium cytoplasmic expression),
and ‘3’ (high cytoplasmic expression), and in addition ‘ ’ (no) for
negative nuclear staining or ‘þ’ (yes) for positive nuclear staining.
Staining of SDF-1 was classified in ‘1’ (missing or very low
membrane staining), ‘2’ (medium membrane staining), and ‘3’
(high membrane staining). HercepTest was classified according to
the standard procedures and translated to our classification system
as follows: HercepTest score ‘0’ and ‘1þ’ as ‘1’ (negative for Her2/
neu expression), score ‘2þ’ as ‘2’ (weak positive), and score ‘3þ’
as ‘3’ (strong positive). Results of both independent interpretations
(already the average of the three biopsies per patient on the
microarrays) were averaged and newly classified (1.00–1.66¼‘1’,
1.67–2.33¼‘2’, and 2.34–3.00¼‘3’). Data were analysed statisti-
cally with SPSS 13 (SPSS, Chicago, IL, USA). P-values below 0.05
were considered statistically significant. P-values above 0.1 were
signed simply as NS (not significant). P-values in between were
signed NS, with the corresponding P-value in parentheses.
Correlations among clinicopathologic parameters were calculated
using the Pearson’s w
2 or Fisher’s exact test as appropriate and
were corrected for multiple testing (Bonferroni–Holmes). Correla-
tion of staining intensities of the putative oncoproteins among
each other and with International Federation of Gynecology and
Obstetrics (FIGO) stages was calculated using the Spearman’s
Correlation Test and corrected for multiple testing (Bonferroni–
Holmes).
Univariate Cox models were used to demonstrate the influence
of known prognostic factors and the four potential new prognostic
factors. For each of the new factors, a multiple Cox model with
known prognostic factors as adjustment variables was calculated.
RESULTS
Description of patient cohort
Clinical and histopathological characteristics of patients included
in this study show a typical ovarian cancer population and are
presented in Table 1. Mean age of patients at first diagnosis was
58.6 years (range 27.6–87.2 years). 54.7 of patients with malignant
tumours had serous adenocarcinomas and 62.5% had stage III/IV
disease. Of the 128 patients with malignant tumours, 81 patients
(67.5%) received carboplatin–paclitaxel-based standard chemo-
therapy, nine patients (7.5%) received cisplatin–cyclophospha-
mid-based chemotherapy, 14 patients (11.7%) another regimen,
and 16 patients (13.3%) no systemic therapy at all. For eight
patients, no information about systemic treatment was available.
Median follow-up for patients with malignant tumours was 43.7
months (range 0.4–168.7 months), and 39 patients (26.4%) had
already died. None of the patients with borderline tumours died
during the follow-up time of median 45.7 months (range 0.6–120.9
months).
HER2/neu overexpression in ovarian cancer samples
HER2/neu protein was stained with the DAKO HercepTest and
interpreted following the standard procedures for breast cancer
diagnosis. 35 out of 127 cancer tissues (27.6%) of patients with
malignant tumours were found to overexpress the HER2/neu gene
product including four tissues with high HER2/neu expression
(3þ) (Table 2). Only three out of 20 tissues (15.0%) of patients
with borderline tumours showed overexpression of HER2/neu,
none of them with high expression. Table 2 shows the prevalence
of tumour staining scores with respect to histology, FIGO stage,
and grade. There was no difference between HER2/neu staining
regarding these clinical characteristics.
CXCR4 expression in ovarian cancer samples
We examined expression of CXCR4 in the same tissues as
described above. CXCR4 expression was found independently in
the cytoplasm and/or in the nucleus (Salvucci et al, 2005).
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distinguishable from high cytoplasmic staining. This is in
accordance with similar experiments with breast cancer tissues
and the same primary antibody (Salvucci et al, 2005). Cytoplas-
matic staining was classified as 1 (missing or weak expression), 2
(medium expression), and 3 (high expression). Nuclear expression
was classified as ‘Yes’ (visible staining) and ‘No’ (no visible
staining of the nucleus) (Figure 1, Table 2). The relatively low
standard deviations within the three corresponding tumour cores
from different positions of the tumour on the tissue microarray
(the mean of the standard deviations over all patients equals 0.22)
points to a low variability of cytoplasmic CXCR4 expression within
one tumour. In 53.8% of malignant tumours, cytoplasmatic
CXCR4 expression was medium or high (2/3) and 21.8% showed
CXCR4 staining of the nucleus. There was no correlation of CXCR4
staining in the cytoplasm and the nucleus (Table 3). No significant
different expression of nuclear and cytoplasmic staining regarding,
histology, FIGO stage, or grade could be found; only the nuclear
expression appeared indirectly correlated to grading (but not
significant after correction for multiple testing), starting at 37.5%
positive tumours for grade 1, 30.0% positive tumours for grade 2,
and ending with 12.7% positive tumours for grade 3 (Table 2).
Neither the cytoplasmatic nor the nuclear CXCR4 expression was
correlated with the HER2/neu expression in ovarian cancer tissues
(data not shown). CXCR4 stained high or medium in the cytoplasm
of 50% borderline tumours and in 33.3% of borderline tumour
nuclei, which was not different from the staining frequencies in
malignant tumours (Table 2).
SDF-1 abundance in ovarian cancer tissues and stroma
To get some insight into the functionality of CXCR4 receptors on
the surface of ovarian cancer cells, we included an analysis of SDF-1
on the cell membrane – the only known soluble ligand of CXCR4.
For SDF-1, 32.0% of membranes of malignant tumour samples
stained medium or high (2/3) (Figure 2). Positive staining did not
correlate with any clinicopathologic characteristics like histology,
FIGO stage, or grade (Table 2). Membranous SDF-1 staining
correlated significantly with the cytoplasmatic CXCR4 expression,
Table 1 Clinicopathologic characteristics of patients
Ovarian tumours n¼148 Mean7s.d.
Age (years)
Borderline 20 54.7713.9
Malignant 128 59.2712.1
Histology
Borderline 20 13.5%
Serous 70 47.3%
Endometrioid 24 16.2%
Mucinous 7 4.7%
Clear cell 7 4.7%
Mixed 8 5.4%
Undifferentiated 12 8.1%
FIGO stage
1 51 (17 borderline) 34.5%
2 14 9.5%
3 75 (3 borderline) 50.7%
4 8 5.4%
Grade
Borderline 20 13.5%
G1 21 14.2%
G2 26 17.6%
G3 70 47.3%
Missing 11 7.4%
Follow up (months) Median Range
Borderline 45.7 0.6–120.9
Malignant 43.7 0.4–168.7
Abbreviations: FIGO¼International Federation of Gynecology and Obstetrics;
s.d.¼standard deviation.
Table 2 Correlation of HER2/neu, cytoplasmic or nuclear CXCR4 expression, and SDF-1 abundance with clinicopathologic characteristics
HER2/neu CXCR4 SDF-1
Cytoplasmic Nuclear
1
a 23NP123NP Yes/no P 123NP
Malignity NS
b NS
b NS
c NS
b
Borderline 17 3 0 20 9811 5 5/15 12 6 1 19
Malignant 92 31 4 127 55 51 13 119 22/101 87 30 11 128
Histology (malignant) NS
b NS
b NS
b NS
b
Serous 52 14 3 69 25 34 6 65 10/55 46 17 7 70
Endometrioid 18 5 1 24 10 9 4 23 5/20 15 6 3 24
Mucinous 6 1 0 7 3 3 0 6 4/6 6 1 0 7
Clear cell 5 2 0 7 5 1 0 6 1/5 6 1 0 7
Mixed 5 3 0 8 4 2 1 7 1/4 5 2 1 8
Undifferentiated 6 6 0 12 8221 2 1/11 9301 2
FIGO stage NS
NS (0.064)
d NS
d NS
d NS
d
1 42 9 0 51 18 23 5 46 11/41 33 11 6 50
2 1 22 01 4 8401 2 2/10 9501 4
3 51 20 3 74 33 30 8 71 14/58 53 17 5 75
4 43 1 8 521 8 0 / 7 431 8
Grade (w/o borderline) NS
b NS
b NS
b NS
b
G 1 1 83 02 1 6931 8 6/16 12 7 2 21
G2 18 7 1 26 12 11 2 25 6/20 20 3 3 26
G3 46 21 2 69 31 28 7 66 7/55 47 19 4 70
aFor consistency with our rating system, HER2/neu scores were translated as follows: ‘0’ and ‘1+’¼‘1’, ‘2+’¼‘2’, and ‘3+’¼‘3’.
bPearson’s w
2 test (corrected).
cFisher’s exact test
(corrected).
dSpearman’s correlation test, corrected for multiple testing. Abbreviations: NS¼not significant, FIGO¼International Federation of Gynecology and Obstetrics.
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interestingly, – indirectly, also as a trend with the nuclear CXCR4
expression (Spearman correlation rr¼ 0.244; P¼0.084 after
correction; Table 3). No correlation of SDF-1 abundance and
HER2/neu expression was found (data not shown). Medium or high
(2/3) SDF-1 protein levels were found in 31.5% of membranes of
borderline tumours, which is the same frequency as for malignant
tumour samples. As expected, SDF-1 was expressed at low level in
the stroma of all ovarian cancer cases (data not shown).
Overall survival analysis
For Kaplan–Meier plots with patients with malignant tumours, the
parameters were dichotomised in two groups, one with low (1)
HER2/neu or cytoplasmic CXCR4 expression or SDF-1 abundance
and one with medium or high (2/3) expression/abundance of the
corresponding protein (Figure 3). The only parameter with
significant univariate influence on prognosis was HER2/neu
(P¼0.004; Figure 3A). The medium overall survival for patients
with HER2/neu overexpression was 40.3 months compared with
168.7 months for the HER2/neu-negative patients. Type of systemic
chemotherapy (carboplatin–paclitaxel based vs other) had no
significant influence on the prognostic value of the HER2/neu
overexpression status (data not shown).
All other parameters – cytoplasmic or nuclear CXCR4 expres-
sion and SDF-1 abundance – had no influence on overall survival.
The 75% percentile of overall survival for all groups with low or
high expression of each of these three parameters was very similar
and ranged from 28.6 to 33.4 months (Figure 3B–D). There was no
subgroup, for example, histological, FIGO stage, or grade, which
resulted in a significant influence of these three parameters under
investigation on patient prognosis (data not shown). There was
also no combination of variables, for example, only CXCR4 and
SFD-1-positive tumours compared with others, which resulted in a
significant influence on patient prognosis (data not shown).
1
Low nuclear
CXCR4
High nuclear
2
3
Figure 1 Immunohistochemistry staining of CXCR4 on different
malignant ovarian cancer tissues. In the left-hand panel, representative
tissues with low nuclear and low (1), medium (2), or high (3) cytoplasmic
CXCR4 stainings are shown. In the right-hand panel, representative tissues
with high nuclear and low (1), medium (2), or high (3) cytoplasmic CXCR4
stainings are shown.
Table 3 Correlation of SDF-1 abundance and cytoplasmic or nuclear
CXCR4 expression
CXCR4 cyt. CXCR4 nuc.
Borderline
NS
a 123 NS
a No Yes
SDF-1 1 730 1 52
2 240 2 33
3 010 3 10
Malignant
o0.001
a 123 NS (0.084)
a No Yes
SDF-1 1 45 31 3 1 47 19
2 91 3 7 2 22 3
3 173 3 10 0
NS
a
CXCR4 nuc. No 36 33 10
Yes 12 8 2
aSpearman’s correlation test (corrected). NS, not significant.
1
SDF-1
2
3
Figure 2 Immunohistochemistry staining of SDF-1 (CXCL12) of different
malignant ovarian cancer tissues. The representative stainings of tissues with
low (virtually missing) (1), medium (2), and high (3) SDF-1 abundance are
shown. Notice prevalent SDF-1 staining of endothelium in the right upper
corner of the middle picture.
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but negative staining for SDF-1 was not significantly higher
compared with patients with negative CXCR4 expressing tumours
in the same background (relative risk of 1.57, P¼0.281).
A multiple analysis revealed FIGO stage and grade as the only
independent prognostic factors for overall survival in our cohort of
128 malignant ovarian cancer patients. Of all parameters under
investigation, only HER2/neu showed negative trend, also, for
overall survival (relative risk of 1.92, P¼0.074; Table 4) after
multiple corrections also a negative trend also for overall survival
(relative risk of 1.92, P¼0.074; Table 4).
A multiple analyses of the impact of HER2/neu expression on
overall survival, using both CXCR4 expressions (nuclear and
cytoplasmic) and the SDF-1 abundance as correcting variables
showed that there was no influence of one of these three parameters
on the prognostic value of HER2/neu expression (data not shown).
Survival analysis was performed only with patients of malignant
tumours, because patients with borderline tumours had a significant
better prognosis, with no cases of death during follow-up.
DISCUSSION
Hereditary ovarian and breast cancers are based on germline
mutations in the same cancer susceptibility genes, BRCA1 and
BRCA2, suggesting similar pathways of oncogenesis at least for a
fraction of these diseases. Moreover, both cancer types show, in
a comparable percentage, overexpression of the oncoprotein
HER2/neu.
In breast cancer, the diagnostic and therapeutic possibilities of
HER2/neu expression are well explored. Well known since decades
as an adverse prognostic factor, the more recent insight that breast
cancers expressing HER2/neu are more susceptible to anthra-
cycline-based chemotherapy (Pritchard et al, 2006) as well as
the introduction of the HER2/neu antibody trastuzumab into
the adjuvant setting has had significant impact on the prognosis of
this particular subgroup of breast cancer patients (Slamon et al,
2001).
In ovarian cancer, the prognostic influence of HER2/neu is still a
matter of debate and the therapeutic capacity of the available drugs
to target the HER2/neu pathway are insufficiently explored. Even
the percentage of HER2/neu-positive patients varies considerably
among individual studies. The lack of knowledge about the
prognostic and therapeutic impact of HER2/neu expression in
ovarian cancer may be partly explained by its lower prevalence in
the general population resulting in slower patient recruitment and
underpowered studies. Besides this simplistic view, the possibility
of a less significant and/or different influence of HER2/neu
expression in breast and ovarian cancer could be another and
more challenging explanation.
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Figure 3 Plots of Kaplan–Meier estimates for overall survival of patients with tumour tissues with low (1) or high (2/3) HER2/neu (A), low (1) or high
(2/3) SDF-1 (B), low (1) or high (2/3) cytoplasmic CXCR4 (C), and low (1) or high (2/3) nuclear CXCR4 (D) expression/abundance. P-values are from the
log-rank test.
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been extensively studied, its role in oncogenesis is still far from
being understood. Recently, interesting functional data were
generated, showing that HER2/neu enhances expression of the
chemokine receptor CXCR4. CXCR4 is furthermore crucial for
HER2/neu induced invasion, migration, and adhesion activities,
and in vitro HER2/neu protects CXCR4 from ligand-induced
protein degradation. CXCR4 is furthermore responsible for HER2/
neu-induced lung metastases in vivo. These in vivo findings are
corroborated by the observation that CXCR4 is upregulated in
HER2/neu overexpressing primary breast tumour tissues and is
correlated with poor patient survival (Li et al, 2004). The findings
that cytoplasmic CXCR4 expression is elevated in breast cancer
samples, and that higher expression of CXCR4 is associated with
parameters of tumour aggressiveness, and a poor prognosis was
later confirmed in an independent patient population (Salvucci
et al, 2005).
In accordance with the majority of publications, we found
HER2/neu to be overexpressed in about a quarter of malignant
tumours. HER2/neu-positive patients had a significantly shorter
overall survival. There was a trend that HER2/neu-positive patients
were diagnosed with a higher FIGO stage, resulting in the fact that
in a multivariate model HER2/neu positivity did not hold as an
independent variable. HER2/neu-positive tumours did not show a
higher expression of cytoplasmic CXCR4 staining, which was
positive in over half of the cases and correlated closely with the
expression of its ligand SDF-1 as expected. There was no impact of
cytoplasmic and nuclear CXCR4 expression or SDF-1 abundance
on overall survival (Figure 3 and Table 4).
This is in contrast to breast cancer and also other forms of
cancer where CXCR4 has been shown to be of significant
prognostic influence like oesophageal cancer (Kaifi et al, 2005),
colon cancer (Kim et al, 2005), early-stage non-small-cell
lung cancer (Spano et al, 2004), low-grade glioma (Salmaggi
et al, 2005), malignant melanoma (Scala et al, 2005), osteosarcoma
(Laverdiere et al, 2005), oral squamous cell carcinoma (Almofti
et al, 2004), and adult acute myeloid leukaemia (Rombouts et al,
2004). One explanation might be the importance of distant
metastases to SDF-1 expressing tissues on the cause of death in
most of these other forms of cancer. Patients only rarely die of
their primary cancer, but rather as a result of metastatic disease. In
ovarian cancer, recurrences in the pelvis and, in most cases even
within the peritoneum, which has a comparable microenvironment
as the primary tumour, are the main causes for death. In our
series, only 6.3% (eight out of 128) of patients had distant
metastases at primary diagnosis (FIGO 4) and therefore a
statistical analysis for CXCR4 overexpression from this group
was fruitless. No difference in HER2/neu, CXCR4, and SDF1
expression (or combination) could be found in this small
subgroup. Most patients with ovarian cancer die on local
recurrences (transcoelomic metastases) within the peritoneum
and not on distant metastases (haematogenous metastases)
(Vaccarello et al, 1995). In fact, only about 15% of patients get
distant metastases during their course of disease (Sood et al, 1999).
Further support came from the more recent finding that
intraperitoneal chemotherapy is equivalent and even superior to
systemic therapy in this disease (Armstrong et al, 2006). Thus,
the biology of ovarian cancer seems to be quite different from
other epithelial cancers (Naora and Montell, 2005). As an example,
normal cells of the ovarian surface epithelium express only little or
even no E-cadherin and have both mesenchymal and epithelial
features, whereas many primary ovarian carcinomas express
higher levels of E-cadherin. The gain of E-cadherin expression,
completely unexpected for tumour cells, may result in an
Table 4 Hazard ratios for overall survival of the 128 patients with malignant tumors after multiple Cox regression analyses of HER2/neu overexpression,
SDF-1 abundance, and cytoplasmic or nuclear CXCR4 expression
HER2/neu (0/1+ vs 2+/3+) SDF-1 (1 vs 2/3) CXCR4 cyt. (1 vs 2/3) CXCR4 nuc. (No vs Yes)
HR
a 95% CI
b P HR 95% CI P HR 95% CI P HR 95% CI P
Histology
Serous 1.00 1.00 1.00 1.00
Non-serous 1.06 0.50–2.22 0.875 1.24 0.60–2.53 0.559 1.34 0.65–2.78 0.434 1.10 0.48–2.52 0.819
FIGO stage
I+II 1.00 1.00 1.00 1.00
III+IV 15.38 1.96–125.00 0.009 19.61 2.54–142.86 0.004 18.18 2.37–142.86 0.005 10.75 1.34–83.33 0.025
Grade
G1+G2 1.00 1.00 1.00 1.00
G3 3.47 1.19–10.10 0.022 3.60 1.24–10.42 0.019 3.32 1.15–9.62 0.027 6.21 1.38–27.78 0.017
HER2/neu
0/1+ 1.00
2+/3+ 1.92 0.94–3.94 0.074 NA
c NA NA
SDF-1
1 1.00
2+3 NA 1.36 0.68–2.75 0.385 NA NA
CXCR4 cyt.
1 1.00
2+3 NA NA 1.37 0.68–2.76 0.379 NA
CXCR4 nuc.
No 1.00
Yes NA NA NA 1.51 0.55–4.08 0.421
aHazard ratio.
b95% confidence interval.
cNot applicable. Abbreviations: FIGO¼International Federation of Gynecology and Obstetrics.
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sadvantage for ovarian cancer cells to colonise new sites in the
peritoneum. The characteristic epithelia–mesenchymal transition
— thought to be necessary for distant metastases, – as well as for
the development of distant (haematogenous) metastases, seems to
play a subordinate role in the course of ovarian cancer disease.
Thus, our finding of the missing influence of CXCR4 expression
(and SDF-1 abundance) on patient outcome is in line with the
above-mentioned fact that haematogenetic metastases to organs
with high SDF-1 expression is relatively rare in ovarian cancer.
Molecular mechanisms for these differences are not well under-
stood in detail (Tan et al, 2006) but are in the focus of increasing
scientific endeavours.
In summary, no clear-cut relationship between HER2/neu,
CXCR4, SDF1, and metastasis and/or prognosis as obvious for
breast cancer was found in ovarian cancer. If HER2/neu expression
is of biological relevance and not merely reflecting a more
advanced stage of the disease, other than CXCR4-mediated HER2/
neu activities have to be explored for ovarian cancer.
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